A Single and Multiple Ascending Dose study of AB-423 in in Healthy Volunteers

Trial Profile

A Single and Multiple Ascending Dose study of AB-423 in in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs AB 423 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 14 Mar 2018 Status changed from recruiting to completed,According to an Arbutus Biopharma Corporation media release.
    • 02 Nov 2017 According to an Arbutus Biopharma Corporation media release, results from this trial are expected in mid-2018.
    • 24 Oct 2017 Interim results (n=32) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top